United Therapeutics Corporation (NASDAQ:UTHR) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued on Friday.

A number of other research firms have also recently commented on UTHR. Zacks Investment Research cut United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. BidaskClub cut United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. UBS AG reaffirmed a “sell” rating and issued a $106.00 price target on shares of United Therapeutics Corporation in a research note on Thursday, July 6th. Finally, Jefferies Group LLC reaffirmed a “sell” rating and issued a $105.00 price target on shares of United Therapeutics Corporation in a research note on Thursday, June 8th. Six analysts have rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $134.50.

Shares of United Therapeutics Corporation (NASDAQ:UTHR) opened at 120.82 on Friday. United Therapeutics Corporation has a 52-week low of $110.90 and a 52-week high of $169.89. The company has a 50 day moving average price of $130.10 and a 200-day moving average price of $130.86. The stock has a market capitalization of $5.25 billion, a P/E ratio of 14.01 and a beta of 1.52.

United Therapeutics Corporation (NASDAQ:UTHR) last posted its earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) EPS for the quarter, missing the Zacks’ consensus estimate of $3.61 by $4.86. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The business had revenue of $444.60 million for the quarter, compared to analyst estimates of $391.53 million. During the same quarter last year, the business earned $4.42 earnings per share. United Therapeutics Corporation’s revenue was up 7.8% on a year-over-year basis. On average, analysts predict that United Therapeutics Corporation will post $10.09 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/09/united-therapeutics-corporation-uthr-downgraded-by-valuengine.html.

In other United Therapeutics Corporation news, Director Christopher Causey sold 580 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $134.48, for a total value of $77,998.40. Following the transaction, the director now directly owns 3,295 shares of the company’s stock, valued at approximately $443,111.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Raymond Dwek sold 3,490 shares of the firm’s stock in a transaction that occurred on Friday, June 23rd. The stock was sold at an average price of $131.71, for a total transaction of $459,667.90. The disclosure for this sale can be found here. Insiders sold a total of 25,178 shares of company stock worth $3,289,427 over the last three months. Corporate insiders own 7.80% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in UTHR. Canada Pension Plan Investment Board lifted its stake in United Therapeutics Corporation by 123.8% in the 1st quarter. Canada Pension Plan Investment Board now owns 55,502 shares of the biotechnology company’s stock worth $7,514,000 after purchasing an additional 30,700 shares in the last quarter. State Treasurer State of Michigan increased its holdings in shares of United Therapeutics Corporation by 7.0% during the 1st quarter. State Treasurer State of Michigan now owns 18,300 shares of the biotechnology company’s stock worth $2,477,000 after buying an additional 1,200 shares during the last quarter. State Board of Administration of Florida Retirement System increased its holdings in shares of United Therapeutics Corporation by 11.9% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 75,859 shares of the biotechnology company’s stock worth $10,270,000 after buying an additional 8,047 shares during the last quarter. Advisors Asset Management Inc. increased its holdings in shares of United Therapeutics Corporation by 32.9% during the 1st quarter. Advisors Asset Management Inc. now owns 5,487 shares of the biotechnology company’s stock worth $743,000 after buying an additional 1,358 shares during the last quarter. Finally, Daiwa Securities Group Inc. increased its holdings in shares of United Therapeutics Corporation by 17.4% during the 1st quarter. Daiwa Securities Group Inc. now owns 1,350 shares of the biotechnology company’s stock worth $183,000 after buying an additional 200 shares during the last quarter.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.